
|Videos|January 5, 2015
PFS as an Endpoint in Ovarian Cancer Clinical Trials
Author(s)Jason D. Wright, MD
Jason D. Wright, MD, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.
Advertisement
Clinical Pearls
Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.
- PFS is the most commonly used endpoint for ovarian cancer clinical trials.
- PFS is relatively easily measured and can be measured in a timely fashion.
- However, PFS does not always correlate with overall survival.
Olaparib was recently approved for ovarian cancer.Read more > >
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
5


















